Literature DB >> 29434744

Interleukin-1 receptor-associated kinase 3 downregulation in peripheral blood mononuclear cells attenuates immunosuppression in sepsis.

Qin Xia1, Yupin Zhou2, Xi Wang1, Shukun Fu1.   

Abstract

Sepsis is the leading cause of mortality in intensive care units due to complex inflammatory immune responses and immunosuppression. Recent studies have indicated that the negative regulator of toll like receptors, interleukin-1 receptor-associated kinase 3 (IRAK-3/IRAK-M), serves an important role in immunosuppression during sepsis. In the current study, a cecal ligation puncture model was established in mice using lipopolysaccharide secondary challenge to simulate immunosuppression in sepsis. Peripheral blood mononuclear cells (PBMCs) from this model were then used to evaluate the expression and function of IRAK-M. The results demonstrated that silencing of IRAK-M expression in PBMCs from immunosuppressed mice partially restored the production of pro-inflammatory cytokines. By introducing PBMCs transfected with small-interfering RNA targeting IRAK-M into septic immunosuppressed mice, the survival rate was improved with an increase in splenic CD4+ and CD8+ T cells and a decrease in T cell apoptosis. In conclusion, downregulation of IRAK-M reversed the effects of sepsis on the production of inflammatory cytokines in PBMCs, and improved the survival of septic immunosuppressed mice. These results provide a basis for future studies investigating the immunological mechanisms underlying immune suppression in sepsis.

Entities:  

Keywords:  immune suppression; interleukin-1 receptor-associated kinase 3; sepsis

Year:  2017        PMID: 29434744      PMCID: PMC5776169          DOI: 10.3892/etm.2017.5549

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  IRAK-M is a negative regulator of Toll-like receptor signaling.

Authors:  Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

3.  IRAK-M mediates Toll-like receptor/IL-1R-induced NFκB activation and cytokine production.

Authors:  Hao Zhou; Minjia Yu; Koichi Fukuda; Jinteak Im; Peng Yao; Wei Cui; Katarzyna Bulek; Jarod Zepp; Youzhong Wan; Tae Whan Kim; Weiguo Yin; Victoria Ma; James Thomas; Jun Gu; Jian-an Wang; Paul E DiCorleto; Paul L Fox; Jun Qin; Xiaoxia Li
Journal:  EMBO J       Date:  2013-02-01       Impact factor: 11.598

4.  Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M.

Authors:  Jane C Deng; Genhong Cheng; Michael W Newstead; Xianying Zeng; Koichi Kobayashi; Richard A Flavell; Theodore J Standiford
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

5.  Immunosuppression in patients who die of sepsis and multiple organ failure.

Authors:  Jonathan S Boomer; Kathleen To; Kathy C Chang; Osamu Takasu; Dale F Osborne; Andrew H Walton; Traci L Bricker; Stephen D Jarman; Daniel Kreisel; Alexander S Krupnick; Anil Srivastava; Paul E Swanson; Jonathan M Green; Richard S Hotchkiss
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

Review 6.  Harnessing the biology of IL-7 for therapeutic application.

Authors:  Crystal L Mackall; Terry J Fry; Ronald E Gress
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

7.  Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling.

Authors:  Su-Chang Lin; Yu-Chih Lo; Hao Wu
Journal:  Nature       Date:  2010-05-19       Impact factor: 49.962

Review 8.  Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Authors:  Naeem K Patil; Julia K Bohannon; Edward R Sherwood
Journal:  Pharmacol Res       Date:  2016-07-25       Impact factor: 7.658

9.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Authors:  Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

10.  Immunosuppression in sepsis.

Authors:  Peter A Ward
Journal:  JAMA       Date:  2011-12-21       Impact factor: 157.335

View more
  2 in total

Review 1.  Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets.

Authors:  V Kumar
Journal:  Int Immunopharmacol       Date:  2020-10-12       Impact factor: 4.932

2.  A systematic review and meta-analyses of interleukin-1 receptor associated kinase 3 (IRAK3) action on inflammation in in vivo models for the study of sepsis.

Authors:  Trang H Nguyen; Ilona Turek; Terri Meehan-Andrews; Anita Zacharias; Helen R Irving
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.